AND I QUOTE: "Oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. It has also been shown to reduce cigarettes per day and drinks per day in patients with substance use disorders. Thus far, there have been no significant adverse clinical events from psilocybin and there also have been no verifiable recorded deaths reported. Larger studies need to be performed before the drug can potentially become approved for use in the general population."
Hodge AT, Sukpraprut-Braaten S, Narlesky M,
Strayhan RC. The Use of Psilocybin in the Treatment of Psychiatric
Disorders with Attention to Relative Safety Profile: A Systematic
Review. J Psychoactive Drugs. 2022 Feb 28:1-11. doi:
10.1080/02791072.2022.2044096. Epub ahead of print. PMID: 35225726.
Posts
